TREATMENT OF ASTHMA IN PREGNANCY
Date of issue: July 2026, Version: 1
Summary: Asthma is one of the most common chronic conditions affecting pregnant women, and poorly controlled disease has been associated with increased risks of pre eclampsia, preterm birth, low birth weight, and perinatal mortality. Maternal hypoxia resulting from uncontrolled asthma can directly impair fetal oxygenation, highlighting the importance of maintaining stable respiratory function. Effective control of asthma during pregnancy is therefore essential to optimise both maternal and fetal outcomes.
The hormonal and physiological changes of pregnancy can affect asthma severity. Regular monitoring and tailored management are therefore crucial to minimise exacerbations. Appropriate use of asthma medications has been shown to be safe and effective, reducing the likelihood of acute attacks and improving overall pregnancy outcomes. Pregnant women with asthma should generally be managed as per the non-pregnant patient.
Guidance from NICE/BTS/SIGN on the general management of asthma recommends that the following pharmacological treatments (in various combinations and doses) can be used:
• An inhaled corticosteroid (ICS) plus a short-acting beta-2 agonist (SABA – usually salbutamol, with terbutaline used occasionally)
• An ICS/long-acting beta-2 agonist (LABA) combination inhaler (usually ICS/formoterol combination)
• A leukotriene receptor antagonist (LTRA) – montelukast
• A long-acting muscarinic receptor antagonist (LAMA) – tiotropium
• Theophylline
• Oral corticosteroids – most commonly prednisolone
• Biologics
Data on many asthma medications are limited, although they are widely used and not known to cause harm. Consensus expert opinion is that the risk of inadequately treated asthma during pregnancy outweighs any theoretical risk of asthma medication use.
Routine exposure to asthma medications is not an indication for additional fetal monitoring. Women with severe asthma exacerbations in pregnancy require careful management which may include additional monitoring of fetal growth and wellbeing. Other risk factors which could independently increase the risk of adverse pregnancy outcome may also be present in individual cases. Such factors are important to consider when performing case-specific risk assessments.
This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.
If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.
If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.